Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Mindbio Therapeutics Corp. ( (TSE:MBIO) ) is now available.
MindBio Therapeutics Corp. is advancing commercialization of its AI voice-based drug and alcohol intoxication detection platform by targeting large-scale deployment in the mining sector. The company’s CEO has met with mining and health executives in South America to explore using its gate-based, voice-activated screening solution as a first-line, non-invasive test for substances including alcohol, hallucinogens, amphetamines, cocaine and cannabis, in a region where drug and alcohol screening is government mandated and traditional testing is costly, slow and invasive. By aiming to replace or supplement existing saliva, urine, blood and breath tests, MindBio is positioning its proprietary AI platform as a scalable safety tool that could reduce substance-related workplace accidents, production delays and associated costs, opening a significant global market opportunity in an industry heavily impacted by intoxication-related incidents.
More about Mindbio Therapeutics Corp.
MindBio Therapeutics Corp. is a Vancouver-based biotechnology company specializing in drug and alcohol research and AI-driven health prediction technologies. Leveraging speech analytics and machine learning, it has developed a voice- and AI-powered prediction model to detect drug and alcohol intoxication for both consumer and enterprise applications, with a focus on workplaces, law enforcement, mental health, and telehealth environments.
Average Trading Volume: 8,292
Technical Sentiment Signal: Sell
Current Market Cap: C$2.35M
See more insights into MBIO stock on TipRanks’ Stock Analysis page.